Cutia Therapeutics (2487) fair value: what the stock is really worth
As of Sep 30, 2026: fair value of Cutia Therapeutics HK$2.00, price HK$1.02, upside +96.1%, quality 40 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Cutia Therapeutics for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
40‑month range HK$0.9000 – HK$30.90 · fair‑value band HK$1.32 – HK$2.50 · the HK$1.02 price screens below the HK$2.00 fair value. Dashed = 300-day average. As of Sep 27, 2026.
Follow Cutia Therapeutics in your weekly email
Every Wednesday you see whether Cutia Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Cutia Therapeutics an investment holding company, engages in the research, development, manufacture, and commercialization of scalp diseases and care products, and skin care products in the People's Republic of China and Hong Kong.
Show more
Cutia Therapeutics an investment holding company, engages in the research, development, manufacture, and commercialization of scalp diseases and care products, and skin care products in the People's Republic of China and Hong Kong. It focuses on the dermatology treatment and care therapeutic areas, including scalp diseases and care, skin diseases and care, topical anesthesia and localized adipose accumulation management medication. The company provides CU-40102, a topical finasteride spray for androgenetic alopecia treatment; and CU-10201, a topical 4% minocycline foam for acne vulgaris treatment. It is also involved in the development of CU-20401, a recombinant mutant collagenase, currently under Phase II clinical trial for submental adipose accumulation (submental fat); CU-40101, a topical small molecule thyroid hormone receptor agonist liniment, currently completed Phase I clinical trial for the treatment of androgenetic alopecia; and CU-30101, a localized topical lidocaine and tetracaine compound topical anesthesia cream, completed Phase III clinical trial for surface dermatologic operations. In addition, the company provides CATAME, a technology platform that enables the development of a wide range of product dosage forms and the relevant formulation technology. Further, it offers product pipeline of creams, sprays, ointments, aerosol foams and other dosage forms through the CATAME platform. The company was incorporated in 2019 and is headquartered in Shanghai, China.
Stock analysis
Cutia Therapeutics (2487) currently trades at HK$1.02, while our model-based Fair Value estimate is HK$2.00, implying the stock looks roughly 49.0% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 93/100, which puts the evidence level at low.
Scenario range: HK$1.32 (bear) to HK$2.50 (bull), the price of HK$1.02 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Cutia Therapeutics reported revenue of 336M CNY in FY2025 versus 2.0M CNY in FY2021, a compound +258.4%/yr. Reported net income was −340M CNY in FY2025.
Key figures
Market cap HK$1.0B (≈ $133M) · P/S ratio 3.11 · EPS (TTM) HK$−0.7500 · Net margin −101% · Return on equity −36.6% · Return on assets (EBIT) −24.3% · Operating margin −36.6% · Revenue (TTM) 336M CNY.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 37 out of 100 (low confidence).
What moves the price
The share trades about 89% below its 52-week high and 13% above its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 96%, 2487 screens cheaper than that median.
Fair Value models
Bear HK$1.32Fair Value HK$2.00Bull HK$2.50
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+20.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+209.2%
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−8,831.5% (2021) → −91.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 633 stocks
Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score39 · Below median
Fair Value upside+96.1% · Top 25%
Profitability
Return on assets−14.3% · Below median
Net margin (TTM)−101.2% · Bottom 25%
Operating margin (TTM)−36.6% · Bottom 25%
Growth and dividend
Revenue growth46.6% · Top 25%
Balance sheet
Debt / equity0.10× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Cutia Therapeutics Fair Value". https://www.fairvalue-calculator.com/stock/2487
Frequently asked questions
Is Cutia Therapeutics (2487) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of HK$2.00 versus a price of HK$1.02, about +96% upside (undervalued).
What is the fair value of 2487?
Our model-based fair value for Cutia Therapeutics is HK$2.00 (as of Sep 27, 2026), built from audited fundamentals. The current price: HK$1.02.
What is the quality score of 2487?
Cutia Therapeutics has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cutia Therapeutics (2487)?
Our model-based price target is the fair value of HK$2.00 (as of Sep 27, 2026) from 1 valuation models. Cautious scenario HK$1.32, optimistic scenario HK$2.50. It is a calculation from audited fundamentals, not an analyst target.
What is the Cutia Therapeutics stock forecast for 2026?
Our models put fair value at HK$2.00, about +96% upside versus a price of HK$1.02 (undervalued). Cautious scenario HK$1.32, optimistic scenario HK$2.50. The calculation is refreshed regularly with new filings.
What is the revenue of Cutia Therapeutics (2487)?
Cutia Therapeutics reported trailing-twelve-month revenue of about 336M CNY (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of Cutia Therapeutics (2487)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cutia Therapeutics it is HK$2.00 per share (as of Sep 27, 2026), against a price of HK$1.02. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Cutia Therapeutics stock overvalued or undervalued in 2026?
As of Sep 27, 2026, 2487 trades below its calculated fair value: price HK$1.02, fair value HK$2.00, a gap of about +96% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2487?
No. The price is what the market pays today (HK$1.02); the fair value is what the company's own numbers justify (HK$2.00). For Cutia Therapeutics the two are HK$0.9800 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cutia Therapeutics worth?
The market values Cutia Therapeutics at about HK$1.0B (market capitalisation, as of Sep 27, 2026). Per share that is HK$1.02; our models calculate a fair value of HK$2.00 per share.
What do the bullish and bearish scenarios say about 2487?
Our models span a range for Cutia Therapeutics: cautious scenario HK$1.32, base HK$2.00, optimistic HK$2.50 per share (as of Sep 27, 2026, price HK$1.02). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Cutia Therapeutics (2487)?
Balance-sheet figures for Cutia Therapeutics (as of Sep 27, 2026): return on equity −36.6%, debt of 0.10 per unit of equity. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is 2487 from its 52-week high?
Cutia Therapeutics trades at HK$1.02, about 89% below its 52-week high of HK$9.05 and 13% above the low of HK$0.9000 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of HK$2.00 is for.
Which stocks are comparable to Cutia Therapeutics?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cutia Therapeutics stock attractive at the current price?
The data as of Sep 27, 2026: price HK$1.02, calculated fair value HK$2.00 (+96%), Quality Score 40/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2487 calculated?
We run Cutia Therapeutics through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$2.00, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. Cutia Therapeutics currently trades 49 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cutia Therapeutics (2487)?
The closing price on Sep 30, 2026 was HK$1.02. Our model-based fair value is HK$2.00, about +96% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cutia Therapeutics right now?
The large discount to fair value meets weak quality (40/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (HK$1.32). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (HK$1.32 to HK$2.50) leaves room in how you read the outcome.
Key figures of Cutia Therapeutics
How large is the market capitalisation of Cutia Therapeutics (2487)?
The market capitalisation of Cutia Therapeutics is HK$1.0B (≈ $133M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cutia Therapeutics (2487)?
The price-to-sales ratio of Cutia Therapeutics is 3.11 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Cutia Therapeutics (2487)?
Earnings per share at Cutia Therapeutics are HK$−0.7500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Cutia Therapeutics (2487)?
The net margin of Cutia Therapeutics is −101% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Cutia Therapeutics (2487)?
The return on equity (ROE) of Cutia Therapeutics is −36.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cutia Therapeutics (2487)?
On an EBIT basis the return on assets of Cutia Therapeutics is −24.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cutia Therapeutics (2487)?
The operating margin of Cutia Therapeutics is −36.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cutia Therapeutics (2487)?
Revenue at Cutia Therapeutics is growing +46.6% versus a year earlier (3y avg +209%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Cutia Therapeutics (2487) generate?
The free cash flow of Cutia Therapeutics is −303M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Cutia Therapeutics (2487) carry?
The net debt of Cutia Therapeutics is 51.8M CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Cutia Therapeutics in the live analysis
One click puts Cutia Therapeutics on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
